Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF AUGUST 10, 2022 SAM #7558
SOURCES SOUGHT

65 -- Sources Sought: Purchase of thirty (30) vials of Gibco Human Spheroid-Qualified Hepatocytes (Brand-name or equal). This is a COVID-19 Action

Notice Date

8/8/2022 8:56:32 AM
 

Notice Type

Sources Sought
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

75N95022Q00510
 

Response Due

8/15/2022 6:00:00 AM
 

Point of Contact

Renato Gomes
 

E-Mail Address

renato.gomes@nih.gov
(renato.gomes@nih.gov)
 

Small Business Set-Aside

SBA Total Small Business Set-Aside (FAR 19.5)
 

Description

Description:�This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS may submitted a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background: The National Institutes of Health (NIH) is the nation�s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people�s health and save lives. NCATS is one of 27 Institutes and Centers at the NIH and its mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The NCATS DPI plans, conducts and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum. NCATS has become a key partner in the Antiviral Program for Pandemics (APP), a multi-agency initiative that includes National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA), to accelerate antiviral development through early discovery and preclinical development of safe and effective oral antivirals. The initial priority for the APP is to develop treatments for SARS-CoV-2 and other coronaviruses, with the program expanding to address other virus families with pandemic potential. NCATS will apply its proficiency in drug discovery and development and its cutting-edge technologies to fill critical needs of the APP, such as (i) target validation, (ii) high-throughput screening (HTS) for drug starting points, (iii) medicinal chemistry for lead optimization, and (iv) preclinical, investigational new drug (IND)-enabling development. The APP is also tasked with identifying and developing antivirals for a variety of viruses of outbreak and pandemic potential, including a number of viruses that cause vascular damage (e.g. bunyavirales viruses, flaviviruses, alphaviruses). NCATS DPI will use 2d and 3d spheroid liver models to screen for antivirals within APP against select virus panels using the cryopreserved primary human hepatocytes. Primary human hepatocytes have critical characteristics and properties not present in immortalized or cancer liver cell lines. Culturing primary human hepatocytes as spheroids extends their lifespan by up to 4 fold.����� Purpose and Objectives: The Division of Preclinical Innovation (DPI) within the National Center for Advancing Translational Sciences (NCATS) seeks cryopreserved, primary human liver cells (non-fetal) for use in DPI-APP_Biology� Antiviral Drug Development IDDA DPI (8051491). Project Requirements: For reference purposes, the cryopreserved human cells that meets the need of this requirement is the Gibco Human Spheroid-Qualified Hepatocytes, as follows: Part Number: HMCPSQ Description: Gibco Human Spheroid-Qualified Hepatocytes Quantity: 30 vials See the attached Purchase Description for the complete list of brand-name items, descriptions, and salient characteristics. Contract Type and Anticipated Period of Performance / Delivery Date: The Government anticipates awarding a firm fixed-price purchase order under a future solicitation. The anticipated delivery date is within three (3) weeks after receipt of order (ARO). Delivery shall be made to the below address with FOB Destination. National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, MD 20850 In case domestic sources are available and capable of fulfilling the Government�s need, and a future solicitation is published, the Government will use evaluation preferences in accordance with FAR 25. Capability statement /information sought. Respondents must provide clear and convincing documentation of their capability of providing the products specified in this sources sought notice. Moreover, interested vendors must provide a capability statement for: the difficulty and/or feasibility of the potential requirement or proposed acquisition, possible solutions and approaches that may currently exist in the marketplace, and information regarding innovative ideas or concepts; and information regarding respondents�: (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. written capability statements should demonstrate organization�s capability to provide the brand-name or equal items listed in the Project Requirements section above. If the entity believes to be an authorized resellers of the brand-name product specified in this announcement or it desires to offer an equal product, the entity�s capability statement must include: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the Project Requirements section above; and country of manufacture of the product. The respondent must also provide their Unique Entity ID (UEI) number, organization name, address, point of contact, GSA Schedule (if any), and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. Submission Instructions: � One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages.� The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist.� Facsimile responses are NOT accepted. Responses must be received by 9:00 a.m., Eastern Time, on August 15, 2022, and reference Sources Sought Number 75N95022Q00510. Responses must be submitted by email to Renato Gomes, Contract Specialist, renato.gomes@nih.gov. �Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).�
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/786a2c99eb324e9f9f378dbe3fd9cb28/view)
 

Place of Performance

Address: Rockville, MD 20850, USA

Zip Code: 20850

Country: USA
 

Record

SN06418576-F 20220810/220808230119 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |